Year archive

Sinco Pharmaceuticals Holdings Limited — 2025 filings

All 128 regulatory filings released by Sinco Pharmaceuticals Holdings Limited (6833) in 2025, sourced directly from the official regulator.

128 Filings

2025 Period

2025 filings (128)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE III CLINICAL TRIAL OF TDI01 "ROCK2 INHIBITOR" FOR IDIOPATHIC PULMONARY FIBROSIS Regulatory Filings	2025-12-31	English
VOLUNTARY ANNOUNCEMENT - TQH3906 "TYK2/JAK1 JH2 ALLOSTERIC INHIBITOR" ACHIEVING POSITIVE PROGRESS IN THE PHASE II CLINICAL TRIAL FOR PLAQUE PSORIASIS Regulatory Filings	2025-12-28	English
VOLUNTARY ANNOUNCEMENT - "CULMERCICLIB CAPSULE" APPROVED FOR MARKETING Regulatory Filings	2025-12-12	English
RESULTS OF THE INTERNAL CONTROL REMEDIATION Regulatory Filings	2025-12-05	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQF3250 "ORALLY ADMINISTERED, BIASED GLP-1 RECEPTOR AGONIST" APPROVED BY THE NMPA AND FDA Regulatory Filings	2025-12-04	English
VOLUNTARY ANNOUNCEMENT - "ROTIGOTINE PATCH" APPROVED FOR MARKETING Regulatory Filings	2025-12-03	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF TRD208 "NON-OPIOID MULTI-TARGET MULTI-MODAL ANALGESIC" Regulatory Filings	2025-12-01	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025] Regulatory Filings	2025-12-01	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2025 Regulatory Filings	2025-12-01	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON LM-350 "CDH17 ADC" APPROVED BY THE NMPA Regulatory Filings	2025-11-18	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025 Regulatory Filings	2025-11-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025 Regulatory Filings	2025-11-03	English
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR FIRST-LINE TREATMENT OF ADVANCED BREAST CANCER WAS PRESENTED AT ESMO 2025 Regulatory Filings	2025-10-21	English
KEY FINDINGS OF THE INTERNAL CONTROL REVIEW Governance Information	2025-10-20	English
VOLUNTARY ANNOUNCEMENT - INCLUSION OF TQ-B3234 "SELECTIVE MEK1/2 INHIBITOR" IN THE BREAKTHROUGH THERAPY DESIGNATION PROCESS Regulatory Filings	2025-10-15	English
VOLUNTARY ANNOUNCEMENT - TQB2102 "HER2 BISPECIFIC ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS Regulatory Filings	2025-10-13	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025 Regulatory Filings	2025-10-02	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2025 Regulatory Filings	2025-10-02	English
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS Report Publication Announcement	2025-09-26	English
NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED HOLDERS Report Publication Announcement	2025-09-26	English
2025 INTERIM REPORT Interim / Quarterly Report H1 2025	2025-09-26	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-350 "CDH17 ADC" IN AUSTRALIA Regulatory Filings	2025-09-25	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-2417 "NaPi2b/4-1BB BISPECIFIC ANTIBODY" IN CHINA Regulatory Filings	2025-09-23	English
VOLUNTARY ANNOUNCEMENT - IND APPLICATION OF TQF3250 CAPSULES "GLP-1 RECEPTOR AGONIST" ACCEPTED BY NMPA Regulatory Filings	2025-09-22	English
2025 INTERIM REPORT Interim / Quarterly Report H1 2025	2025-09-19	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2025 Share Issue/Capital Change	2025-09-01	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2025 Regulatory Filings	2025-09-01	English
VOLUNTARY ANNOUNCEMENT - ZONGERTINIB TABLETS APPROVED FOR MARKETING Regulatory Filings	2025-08-29	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Governance Information	2025-08-27	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 Interim / Quarterly Report H1 2025	2025-08-27	English
CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE AND APPOINTMENT OF LEAD INED Board/Management Information	2025-08-27	English
TERMS OF REFERENCE OF NOMINATION COMMITTEE Governance Information	2025-08-27	English
VOLUNTARY ANNOUNCEMENT - DATA FROM FOUR STUDIES OF "TQC3721 (PDE3/4 INHIBITOR)", "TQC2731 (TSLP MONOCLONAL ANTIBODY)" AND "TQC3403 (UMECLIDINIUM BROMIDE AND VILANTEROL TR Regulatory Filings	2025-08-25	English
VOLUNTARY ANNOUNCEMENT - HER2-SELECTIVE TKI "ZONGERTINIB" ONCE AGAIN GRANTED BREAKTHROUGH THERAPEUTIC DESIGNATION BY CDE Regulatory Filings	2025-08-20	English
VOLUNTARY ANNOUNCEMENT - LM-302 "CLDN18.2 ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS Regulatory Filings	2025-08-19	English
Cash Dividend Announcement for Equity Issuer Notice of Dividend Amount	2025-08-19	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025 Interim / Quarterly Report H1 2025	2025-08-18	English
THE SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CONNECTED TRANSACTION RELATING TO THE PROVISION OF FINANCIAL ASSISTANCE TO THE CONNECTED PERSON Regulatory Filings	2025-08-15	English
DATE OF BOARD MEETING Regulatory Filings	2025-08-15	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3142 "BcL-xL PROTAC" ACCEPTED BY NMPA Regulatory Filings	2025-08-12	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3122 "PARP1 INHIBITOR" ACCEPTED BY NMPA Regulatory Filings	2025-08-11	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY THE NMPA Regulatory Filings	2025-08-07	English
VOLUNTARY ANNOUNCEMENT - ROVADICITINIB TABLET "JAK/ROCK INHIBITOR" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS Regulatory Filings	2025-08-06	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINCAL TRIAL OF TQC3302 "ICS/LAMA/LABA SOFT MIST INHALATION FORMULATION" APPROVED BY NMPA Regulatory Filings	2025-08-05	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025 Share Issue/Capital Change	2025-08-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025 Regulatory Filings	2025-08-01	English
NOTIFICATION OF BOARD MEETING Regulatory Filings	2025-08-01	English
VOLUNTARY ANNOUNCEMENT - LM-299 OUT-LICENSING COLLABORATION PROGRESSING SMOOTHLY; US$300 MILLION MILESTONE PAYMENT TO BE RECEIVED SHORTLY Regulatory Filings	2025-07-30	English
VOLUNTARY ANNOUNCEMENT - IND APPROVAL FOR LM-350 "CDH17 ADC" FROM THE US FDA Regulatory Filings	2025-07-24	English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST SUBJECT DOSING OF CLASS 1 INNOVATIVE DRUG TQB6411 (EGFR/c-MET BISPECIFIC ADC) Regulatory Filings	2025-07-22	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION FULL ACQUISITION OF LANOVA MEDICINES M&A Activity	2025-07-22	English
DISCLOSEABLE TRANSACTION - FULL ACQUISITION OF LANOVA MEDICINES M&A Activity	2025-07-15	English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF CULMERCICLIB CAPSULE FOR FIRST-LINE TREATMENT OF BREAST CANCER Regulatory Filings	2025-07-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025 Regulatory Filings	2025-07-07	English
VOLUNTARY ANNOUNCEMENT - "RECOMBINANT HUMAN COAGULATION FACTOR VIIA N01 FOR INJECTION" APPROVED FOR MARKETING Regulatory Filings	2025-07-03	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025 Regulatory Filings	2025-07-02	English
VOLUNTARY ANNOUNCEMENT - INDICATION OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA APPROVED FOR MARKETING Regulatory Filings	2025-06-30	English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF LM-108 ("CCR8 MONOCLONAL ANTIBODY") INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS Regulatory Filings	2025-06-26	English
VOLUNTARY ANNOUNCEMENT - PRECLINICAL AND CLINICAL DATA ON ROVADICITINIB PRESENTED AT EHA 2025 Regulatory Filings	2025-06-18	English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF TDI01 SUSPENSION ("ROCK2 INHIBITOR") INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS BY CDE Regulatory Filings	2025-06-16	English
VOLUNTARY ANNOUNCEMENT - THE LATEST PROGRESS OF INNOVATION-DRIVEN DEVELOPMENT OF THE GROUP Regulatory Filings	2025-06-13	English
AMENDED AND RESTATED ARTICLES OF ASSOCIATION Governance Information	2025-06-10	English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 10 JUNE 2025 Declaration of Voting Results & Voting Rights Announcements	2025-06-10	English
VOLUNTARY ANNOUNCEMENT Regulatory Filings	2025-06-10	English
VOLUNTARY ANNOUNCEMENT - TQC3721 INHALATION SUSPENSION "PDE3/4 INHIBITOR" OBTAINING APPROVAL FOR PHASE III REGISTRATIONAL CLINICAL STUDY FROM CDE Regulatory Filings	2025-06-09	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025 Share Issue/Capital Change	2025-06-05	English
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART WITH OR WITHOUT ANLOTINIB AS MAINTENANCE TREATMENT FOR NON-SMALL CELL LUNG CANCER WITHOUT PROGRESSION FOLLOWING CHEMORADIOTHERAPY PR Regulatory Filings	2025-06-05	English
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB AS FIRST-LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER PRESENTED AT 2025 ASCO ANNUAL ME Regulatory Filings	2025-06-03	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2025 Regulatory Filings	2025-06-02	English
CONNECTED TRANSACTION IN RELATION TO THE PROVISION OF FINANCIAL ASSISTANCE TO THE CONNECTED PERSON Regulatory Filings	2025-05-30	English
VOLUNTARY ANNOUNCEMENT Regulatory Filings	2025-05-29	English
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I STUDY OF TQB2102 (BISPECIFIC ANTI-HER2 ADC) PRESENTED AT 2025 ASCO ANNUAL MEETING Regulatory Filings	2025-05-27	English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 26 MAY 2025 Declaration of Voting Results & Voting Rights Announcements	2025-05-26	English
VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE III STUDY OF BENMELSTOBART IN COMBINATION WITH ANLOTINIB FOR FIRST-LINE TREATMENT OF SQ-NSCLC PRESENTED IN 2025 ASCO ANNUAL MEETING Regulatory Filings	2025-05-23	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 15 MAY 2025 Declaration of Voting Results & Voting Rights Announcements	2025-05-15	English
2025 SHARE OPTION SCHEME Regulatory Filings	2025-05-08	English
FORM OF PROXY FOR USE AT EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2025-05-08	English
NOTICE OF THE EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2025-05-08	English
(1) PROPOSAL FOR TERMINATION OF THE 2016 SHARE OPTION SCHEME AND ADOPTION OF THE 2025 SHARE OPTION SCHEME; AND (2) NOTICE OF EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2025-05-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025 Share Issue/Capital Change	2025-05-06	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2025 Regulatory Filings	2025-05-06	English
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2025-04-29	English
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS Report Publication Announcement	2025-04-29	English
NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED SHAREHOLDERS Report Publication Announcement	2025-04-29	English
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF) AGM Information	2025-04-29	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-29	English
GENERAL MANDATES TO ISSUE AND BUY BACK SHARES; RE-ELECTION OF DIRECTORS; ADOPTION OF THE NEW ARTICLES; AND NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-29	English
2024 ANNUAL REPORT Annual Report FY 2024	2025-04-29	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF PENPULIMAB INJECTION BY THE US FDA Regulatory Filings	2025-04-25	English
VOLUNTARY ANNOUNCEMENT - 45 RESEARCH RESULTS WILL BE PRESENTED AT 2025 ASCO ANNUAL MEETING (INCLUDING 12 ORAL SESSIONS) Regulatory Filings	2025-04-24	English
ADOPTION OF THE NEW ARTICLES Governance Information	2025-04-23	English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-22	English
NOTICE OF ANNUAL GENERAL MEETING AGM Information	2025-04-22	English
(1) PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) PROPOSED FINAL DIVIDEND; AND (4) NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-22	English
Environmental, Social and Governance Report 2024 Environmental & Social Information	2025-04-22	English
Annual Report 2024 Annual Report FY 2024	2025-04-22	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB3019 (BTK PROTAC)" APPROVED BY NMPA Regulatory Filings	2025-04-09	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2025-04-09	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2025-04-08	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB2101 (ROR1 ADC)" APPROVED BY NMPA Regulatory Filings	2025-04-03	English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF "TQB6411 (EGFR/C-MET BISPECIFIC ADC)"ACCEPTED BY CDE Regulatory Filings	2025-04-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025 Regulatory Filings	2025-04-01	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025 Regulatory Filings	2025-04-01	English
Shareholders' Communication Policy Governance Information	2025-03-28	English
Final Dividend for the year ended 31 December 2024 Notice of Dividend Amount	2025-03-28	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 Earnings Release FY 2024	2025-03-28	English
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR FIRST-LINE TREATMENT OF HR-POSITIVE AND HER2-NEGATIVE ADVANCED BREAST CANCER Regulatory Filings	2025-03-24	English
FINAL DIVIDEND FOR 2024 Notice of Dividend Amount	2025-03-20	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 Annual Report FY 2024	2025-03-20	English
DATE OF BOARD MEETING Report Publication Announcement	2025-03-18	English
VOLUNTARY ANNOUNCEMENT - RESULTS FROM PHASE IB/IIA CLINICAL STUDY OF FIRST-IN-CLASS JAK/ROCK INHIBITOR "ROVADICITINIB" PUBLISHED IN BLOOD Regulatory Filings	2025-03-10	English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE COOPERATION AGREEMENT WITH DELOVA BIOTECH FOR QP001 Regulatory Filings	2025-03-06	English
NOTIFICATION OF BOARD MEETING Regulatory Filings	2025-03-03	English
CHANGE OF HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE Regulatory Filings	2025-03-03	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025 Regulatory Filings	2025-03-03	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025 Share Issue/Capital Change	2025-03-03	English
VOLUNTARY ANNOUNCEMENT - SIGNING OF AN EXCLUSIVE STRATEGIC COOPERATION AGREEMENT WITH SCIWIND BIOSCIENCES REGARDING PROJECT IL-29 Regulatory Filings	2025-02-27	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF THE FIRST GENERIC "TULOBUTEROL PATCHES" Regulatory Filings	2025-02-07	English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "LOXOPROFEN SODIUM CATAPLASMS" Regulatory Filings	2025-02-07	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025 Regulatory Filings	2025-02-05	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025 Regulatory Filings	2025-02-04	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2025-01-16	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2025-01-14	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2025-01-13	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2025-01-10	English
NEXT DAY DISCLOSURE RETURN Transaction in Own Shares	2025-01-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024 Regulatory Filings	2025-01-02	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2024 Regulatory Filings	2025-01-02	English

Filings by year

2026 26 filings
2025 128 filings
2024 150 filings
2023 143 filings
2022 158 filings
2021 142 filings
2020 148 filings
2019 111 filings
2018 112 filings
2017 73 filings
2016 85 filings
2015 45 filings
2014 30 filings
2013 40 filings
2012 41 filings
2011 30 filings
2010 52 filings
2009 36 filings
2008 23 filings
2007 24 filings
2006 24 filings
2005 27 filings
2004 18 filings
2003 4 filings